Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study

Abstract Adenomyosis is a common disorder in premenopausal women that causes dysmenorrhea, pelvic pain and menorrhagia. Considering that adenomyosis is an estrogen-dependent disease, the medical treatment is based on this hormone. Effective and well-tolerated medical treatments for symptomatic adeno...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2014-10, Vol.30 (10), p.726-729
Main Authors: Hirata, Tetsuya, Izumi, Gentaro, Takamura, Masashi, Saito, Ako, Nakazawa, Akari, Harada, Miyuki, Hirota, Yasushi, Koga, Kaori, Fujii, Tomoyuki, Osuga, Yutaka
Format: Article
Language:English
Subjects:
Adenomyosis
Adenomyosis - drug therapy
Adult
dienogest
Female
Humans
Metrorrhagia - chemically induced
Middle Aged
Nandrolone - administration & dosage
Nandrolone - adverse effects
Nandrolone - analogs & derivatives
Nandrolone - pharmacology
pelvic pain
Pilot Projects
Progesterone Congeners - administration & dosage
Progesterone Congeners - adverse effects
Progesterone Congeners - pharmacology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Adenomyosis is a common disorder in premenopausal women that causes dysmenorrhea, pelvic pain and menorrhagia. Considering that adenomyosis is an estrogen-dependent disease, the medical treatment is based on this hormone. Effective and well-tolerated medical treatments for symptomatic adenomyosis are needed. Dienogest, an oral progestin, has been extensively investigated in the treatment of endometriosis. In this report, we present the results on the efficacy and safety of dienogest in the treatment of symptomatic adenomyosis. Seventeen patients with symptomatic adenomyosis were included in this study, of which 15 continued dienogest for up to 24 weeks. Dienogest significantly reduced adenomyosis-associated pelvic pain as well as serum CA-125 and CA19-9 levels. It also demonstrated a modest suppression of estradiol (>50 pg/ mL), which is consistent with the findings of other reports. During treatment, five patients experienced worsening anemia because of metrorrhagia, which is the most frequent adverse effect associated with dienogest. This report suggests that dienogest is an effective and well-tolerated therapy for symptomatic adenomyosis.
ISSN:0951-3590
1473-0766
DOI:10.3109/09513590.2014.926882